The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Guérin) therapy: a retrospective observational study,” published in the ...

RAG-01 is an innovative saRNA therapy designed to upregulate the p21 tumor suppressor gene, a key regulator of cell cycle progression that has been challenging to target with traditional therapies.

Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who ...

“The identification of patients with HR-NMIBC unlikely to respond favorably to intravesical BCG is an unmet need that may facilitate more effective therapy selection and clinical trial enrollment.

Investigators employed artificial intelligence to characterize tissue samples of high-risk NMIBC that were likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG).

Ferring’s Adstiladrin became the first intravesical oncologic virus approved by the FDA for BCG-Unresponsive NMIBC CIS in 2023. Health Canada gave its approval a year earlier in 2022.

Recall that Anktiva plus BCG is one of two intravesical regimens for BCG-unresponsive disease. The other is Adstiladrin, a “non-replicating adenoviral vector-based gene therapy” that was ...

The standard first-line treatment is transurethral resection of the bladder tumor (TURBT) followed by intravesical BCG immunotherapy. However, a significant proportion of patients experience ...